The specific aims of this Phase I SBIR proposal are to determine the feasibility of a novel detection technology for rapid and sensitive detection of influenza virus. Specifically, we will determine if the manual assay is rapid (about 15 minutes), sensitive (as least 100 times as good as, or better than, an FDA approved antigen test in terms of TCID50 units/mL), reproducible (with CV<15%) and specific (without false positive results from potentially interfering bacterial species at concentrations of upto106 cfu/mL). There are five specific aims in the proposed studies, including: ? ? 1. Synthesis, purification and qualification of luciferin - 4,7-di-methyl-O-neuraminic acid substrate - Section D1. Our goal is to obtain at least 1 gram of highly purified substrate (>98% purity by HPLC). ? ? 2. Formulation of the detection mix - Section D2. We will prepare a detection mix that contains all necessary reagents for detection of flu viral neuraminidase. The detection mix will be lyophilized in a single-use detection tube. ? ? 3. Assay optimization - Section D3 ? ? 4. Evaluation of analytical performance - Section D4. Analytical performance of the assay will be evaluated. We will determine the analytical sensitivity for more than 10 strains of human influenza A and human influenza B. ? ? 5. Comparison studies and preliminary evaluation using human samples - Section D5. We will perform comparison studies using FDA-approved antigen-based test and RT-PCR assay. In addition, we will test some samples collected from human subjects. ? ? PUBLIC HEALTH RELVANCE The proposed Phase I SBIR project will evaluate the feasibility of a novel detection technology for rapid and sensitive detection of influenza virus. The technology simplifies the detection process by using a master mix which enables one-step detection, i.e., addition of a sample to the master mix followed by light signal measurement, all performed in the same detection tube. The entire process takes 10-15 minutes. Successful development of the proposed influenza virus test will provide a better alternative for rapid flu diagnosis, thereby significantly improving our medical capability for interpandemic influenza and potential pandemic influenza. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI077117-01A1
Application #
7530062
Study Section
Special Emphasis Panel (ZRG1-IDM-M (12))
Program Officer
Salomon, Rachelle
Project Start
2008-08-15
Project End
2009-07-31
Budget Start
2008-08-15
Budget End
2009-07-31
Support Year
1
Fiscal Year
2008
Total Cost
$196,100
Indirect Cost
Name
Cellex, Inc.
Department
Type
DUNS #
141314521
City
Rockville
State
MD
Country
United States
Zip Code
20850